DOI:
10.1055/s-00034925
Hämostaseologie
LinksClose Window
References
Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J. ONCENOX Investigators.
Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.
Clin Appl Thromb Hemost 2006;
12 (04) 389-396
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.